Ipamorelin vs GHRP-2

Ipamorelin and GHRP-2 stimulate the ghrelin-receptor system. Their research differs: ipamorelin’s often-cited selectivity result comes from animals, and its human bowel-surgery trial left clinical benefit uncertain. GHRP-2 increased how much people ate in small controlled meal experiments. These findings do not establish a ranking for muscle growth, injury recovery or long-term safety.

Research reviewed October 15, 2026. Educational information only.

Two peptides that stimulate the ghrelin-receptor system

Ipamorelin and growth hormone-releasing peptide 2 (GHRP-2) stimulate a receptor system also activated by ghrelin, a hormone involved in growth hormone release and appetite. They are distinct synthetic peptides, with their own exposure, hormone and clinical studies. Raising growth hormone is a physiological effect whose clinical meaning depends on the population and measured outcome.

Ipamorelin is a five-residue peptide in the original pharmacology paper. Its reputation for selectivity comes from comparisons in cells, rats and pigs. The human evidence then moves to healthy-men exposure experiments and postoperative gut recovery. GHRP-2’s directly relevant controlled human experiments examined appetite and the amount eaten during a laboratory meal. Those different questions explain why one study’s apparently larger response cannot establish the better treatment for another purpose.

The main differences

What the animal hormone comparison found

Raun and colleagues (1998) compared ipamorelin with other hormone-releasing signals in experimental systems. In pigs, ipamorelin increased growth hormone, while its ACTH and cortisol responses were not established as higher than those with growth hormone-releasing hormone (GHRH). ACTH is a pituitary signal to the adrenal glands; cortisol is one hormone those glands release during the stress response. GHRP-2 and GHRP-6 increased ACTH and cortisol under their tested conditions.

That experiment supports a particular hormone-selectivity distinction in pigs. It did not measure human adverse-event rates, years of glucose control or outcomes in people using either peptide for athletic recovery. The measured hormone pattern describes these pig experiments, with human adverse-event rates and long-term comparative safety unresolved.

Ipamorelin’s human study moved from hormone release to meal tolerance after surgery

Gobburu and colleagues (1999) studied healthy men and measured ipamorelin and growth hormone after short intravenous infusions, with eight men at each of five exposure levels. The abstract does not establish how many unique men participated across the levels. Released growth hormone peaked around 0.67 hours, while the peptide’s estimated terminal half-life was about two hours. These are separate measurements: hormone release follows peptide exposure without being identical to it.

Beck and colleagues (2014) conducted the later clinical trial, which enrolled 117 adults after small- or large-bowel surgery; 114 formed the main safety and efficacy analysis populations. Investigators compared intravenous ipamorelin with placebo and measured time until patients tolerated a standardized solid meal. Median time was 25.3 hours with ipamorelin and 32.6 hours with placebo. The earlier numerical time was too uncertain to establish a treatment effect (P=0.15), and secondary analyses also did not establish differences. The study leaves a possible benefit unresolved, rather than proving that outcomes were equal.

GHRP-2 increased food intake in controlled human experiments

Laferrère and colleagues (2005) studied seven lean healthy men on separate GHRP-2 and saline-infusion visits. After infusion under the skin, each man ate more at a buffet during the GHRP-2 condition. Mean intake increased 35.9% (P=0.008). Growth hormone rose as well, while the proportions of fat, carbohydrate and protein eaten did not establish a difference. Saline provided a control infusion without the peptide.

Their later randomized crossover experiment (2006) studied ten lean and nine obese, otherwise healthy, weight-stable adults over three visits. Compared with placebo, food intake increased 10.2% in the lower-exposure GHRP-2 condition and 33.5% in the higher-exposure condition. The study did not establish a different response according to obesity status. These are acute meal measurements. They do not demonstrate sustained weight gain, successful nutritional rehabilitation or muscle gain.

The GHRP-2 participants chose how much to eat at a laboratory meal. Ipamorelin’s postoperative patients were recovering bowel function after surgery. Appetite, the amount chosen and the ability to tolerate food are different outcomes, so these experiments cannot establish which peptide improves postoperative recovery or appetite more.

Human exposure cannot be inferred from a hormone peak or rat study

Ipamorelin’s approximately two-hour terminal half-life describes the measured peptide after intravenous infusion in healthy men. Its growth hormone peak around 0.67 hours describes a different substance released by the pituitary. Neither value establishes exposure from every subcutaneous product or the duration of a clinical benefit.

The selected GHRP-2 meal studies used controlled subcutaneous infusions and measured appetite, food intake and hormones. They do not supply a directly comparable human peptide half-life. The duration of a meal experiment does not show how quickly the peptide leaves human blood, and rat clearance findings concern a different species.

Different safety observations do not identify a safer long-term option

Adverse events after treatment began occurred in 87.5% of ipamorelin recipients and 94.8% of placebo recipients in the postoperative trial. FDA’s detailed review discusses two deaths among ipamorelin recipients with major postoperative complications; whether ipamorelin contributed was unclear. It also identifies higher rates of some blood-glucose and potassium abnormalities and missing safety data for the proposed subcutaneous route. The relatively common background events after surgery make raw percentages unsuitable as a safety ranking.

For GHRP-2, FDA identifies reports including increased insulin requirements, infection, pancreatitis and deaths in critically ill patients, with causality unestablished. For injectable or nasal GHRP-2 and some ipamorelin routes, the agency also describes possible immune reactions associated with aggregation and peptide impurities. Small meal studies and animal hormone selectivity do not resolve these clinical or product-quality risks.

FDA’s compounding guidance explains that a compounded drug is not FDA approved and does not receive the agency’s premarket review of safety, effectiveness and quality. No cited experiment compares long-term benefit or safety between these two peptides for muscle growth, healing or healthy aging. The ipamorelin profile and GHRP-2 profile give the individual study settings.

Frequently asked questions

Profiles and related reading

References

1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology. 1998;139(5):552–561. doi:10.1530/eje.0.1390552. PMID:9849822.

   Ipamorelin released growth hormone in cells, rats and pigs. In pigs, responses of ACTH, a pituitary signal to the adrenal glands, and the stress hormone cortisol were not established as higher than responses to growth hormone-releasing hormone (GHRH). GHRP-2 and GHRP-6 raised those hormones under the tested conditions.

2. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical research. 1999;16(9):1412–1416. doi:10.1023/a:1018955126402. PMID:10496658.

   Healthy men received short intravenous ipamorelin infusions. The peptide’s estimated terminal half-life was about two hours; released growth hormone peaked around 0.67 hours. The abstract gives eight men at each level without a unique total.

3. Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease. 2014;29(12):1527–1534. doi:10.1007/s00384-014-2030-8. PMID:25331030.

   After bowel resection, median time to tolerate a solid meal was 25.3 hours with intravenous ipamorelin and 32.6 hours with placebo. This favorable numerical difference did not establish benefit (P=0.15); 114 of 117 enrolled people formed the main analysis populations.

4. Laferrère B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. The Journal of clinical endocrinology and metabolism. 2005;90(2):611–614. doi:10.1210/jc.2004-1719. PMID:15699539.

   Laferrère and colleagues studied seven lean healthy men on separate GHRP-2 and saline visits. After infusion under the skin, the men ate an average 35.9% more at a buffet during GHRP-2 exposure; every participant ate more (P=0.008). Growth hormone also increased, while the proportions of fat, carbohydrate and protein eaten did not establish a difference.

5. Laferrère B, Hart AB, Bowers CY. Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake. Obesity (Silver Spring, Md.). 2006;14(6):1056–1063. doi:10.1038/oby.2006.121. PMID:16861611.

   Laferrère and colleagues tested ten lean and nine obese, otherwise healthy weight-stable adults during three randomized crossover visits. Relative to placebo, food eaten after GHRP-2 infusion under the skin increased by 10.2% in the lower-exposure condition and 33.5% in the higher-exposure condition. Obesity status did not establish a different food-intake response.

6. U.S. Food and Drug Administration. October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee. Ipamorelin-related bulk drug substances briefing document.

   The agency reviews the uncertain postoperative efficacy comparison and safety events, including two deaths among ipamorelin recipients with postoperative complications. Drug causation was unclear; the report does not establish safety for other injectable routes.

7. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Agency assessment; accessed October 15, 2026.

   FDA identifies possible immune reactions and peptide-quality concerns for ipamorelin acetate and injectable or nasal GHRP-2. It describes serious clinical events with uncertain drug attribution and missing safety information for some ipamorelin routes.

8. U.S. Food and Drug Administration. Understanding the Risks of Compounded Drugs. Accessed October 15, 2026.

   FDA explains that compounded drugs are not FDA approved and are not reviewed before marketing for safety, effectiveness and quality in the same way as approved products.